Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. - Wikidata - awgldk - TriplyDB

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

http://www.wikidata.org/entity/Q39685700

about

Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015 Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Reducing costs while enhancing quality of care in MS.To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question.Multiple sclerosis: Is there a safe time to discontinue therapy in MS?Management of multiple sclerosis patients in central European countries: current needs and potential solutions.Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - YES.

P2860

Q36240512-B57EFD27-B387-431B-ABB2-F4CD069DB348 Q36394016-11426441-237A-4306-9086-3AA09F242076 Q38777286-870E75E7-E436-4CEF-BD07-1882024B1404 Q41966640-799EB4D3-8165-4452-923D-6C8422CBD667 Q48307050-A2F62316-9F31-4770-B39C-E898628650AE Q50986289-E751CDC9-ECF1-4D21-8D9B-D38133F48DD9 Q52365115-1188CC82-8708-4BA9-90A2-AEE242DBFE6E Q53181985-EC474FC0-B9C3-4433-860E-B305E20DA83B

P2860

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

http://www.wikidata.org/entity/Q39685700

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Discontinuing disease-modifyin ...... ropensity score-matched study.

@en

Discontinuing disease-modifyin ...... ropensity score-matched study.

@nl

type

label

Discontinuing disease-modifyin ...... ropensity score-matched study.

@en

Discontinuing disease-modifyin ...... ropensity score-matched study.

@nl

prefLabel

Discontinuing disease-modifyin ...... ropensity score-matched study.

@en

Discontinuing disease-modifyin ...... ropensity score-matched study.

@nl

P1433

Q39685700-4C9169B4-DDF6-4CDC-9AD4-4CB3DD2036C2

P1476

Q39685700-214C1DA5-0212-406D-A06C-26DB81FC9B00

P2093

Q39685700-086F93D5-C2F5-4BD2-8F19-72E3205B10A9

Q39685700-087FDA5C-0A73-4195-96A0-ACADC10C43B6

Q39685700-22E7E542-70D0-4B4B-9811-7439ED69B1B5

Q39685700-7AAE753D-F064-4213-8675-2E2794919E7E

Q39685700-7B176DBC-3485-4862-B711-6980D715896F

Q39685700-81213B03-C9C4-4573-AB30-48B0E8300154

Q39685700-B72C48D5-DD7A-4813-8A6B-C77449A2E89F

Q39685700-CA9FD475-ACA7-456F-8720-E16868EC1A27

P2860

Q39685700-16ED883F-859D-473A-902E-ECB0D0F31FFB

Q39685700-2E67042B-529C-4C18-817A-8D9BE81D9E7F

Q39685700-3B4339C0-E813-48CF-9966-79563495095C

Q39685700-42B33FEF-C570-4705-ABD1-6CD4DE55B7F4

Q39685700-5E63562F-4DB9-4D82-8B60-4B75B9CD3CFD

Q39685700-60966F95-2F09-4259-A2E2-25FB90C1285D

Q39685700-BDB6E457-68D1-4A93-B583-BE2B3B62872C

Q39685700-C0109494-3637-414C-A5E2-7558C27861D6

Q39685700-C680427A-476B-4108-8AB2-867F239F13E7

Q39685700-DC14D913-FD24-4663-A50F-22601BDD54FB

P304

Q39685700-92A1F3B6-2E76-4D44-A31F-D8AE0C076C3C

P31

Q39685700-8830BC6F-885E-424E-994C-12CAB4CEAD66

P356

Q39685700-651479B2-8133-495F-8EB1-0ED2A04B63EA

P407

Q39685700-B3B95418-008E-4F6F-9C6F-5FB9FE0CD5A5

P433

Q39685700-046E633B-B3F1-4D75-92F5-4D9584C90A4B

P478

Q39685700-2CD31619-71E9-4A8E-B8F3-383F0D5CFDE1

P50

Q39685700-008B31A2-64E1-4F7D-B7F8-DD34563B7DEF

Q39685700-10DDC893-2918-410C-B925-562F077FA967

Q39685700-1A78C30B-BAEC-4431-90E2-2387D18F798B

Q39685700-2E0A0ECA-9FBE-4A34-881C-9EC1768A72C2

Q39685700-31A037DF-0415-4089-8349-DDEEA05FF259

Q39685700-73BA8E46-9300-44C3-BFB0-BC64B17AA527

Q39685700-8A8BD436-0EF2-47D7-A591-4295CF11514C

Q39685700-B700196B-F1A7-43BD-A1A8-EB4005D4CADB

P577

Q39685700-E8377E92-6793-45E8-B9FE-CF042B4E6F80

P698

Q39685700-DC79F7D5-4984-45B3-8F96-394D09E677FD

P356

JNNP-2016-313760

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Discontinuing disease-modifyin ...... ropensity score-matched study.

@en

P2093

Francois Grand'Maison

http://www.w3.org/2001/XMLSchema#string

Gerardo Iuliano

http://www.w3.org/2001/XMLSchema#string

Jeannette Lechner-Scott

http://www.w3.org/2001/XMLSchema#string

MSBase Study Group

http://www.w3.org/2001/XMLSchema#string

Pierre Duquette

http://www.w3.org/2001/XMLSchema#string

Pierre Grammond

http://www.w3.org/2001/XMLSchema#string

Raymond Hupperts

http://www.w3.org/2001/XMLSchema#string

Tim Spelman

http://www.w3.org/2001/XMLSchema#string

P2860

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.

Interferon β for secondary progressive multiple sclerosis: a systematic review.

Increasing age at disability milestones among MS patients in the MSBase Registry.

P304

1133-1137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP-2016-313760

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

Helmut Butzkueven

Alessandra Lugaresi

Raed Alroughani

Michael Barnett

P577

2016-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27298148

http://www.w3.org/2001/XMLSchema#string